Une alternative attrayante à l’approche traditionnelle de la thérapie génique par addition de gène, ou thérapie par les gènes, consiste à corriger in situ le gène muté. Cette approche par thérapie du gène, ou correction génique, offre potentiellement de nombreux avantages comparée à la thérapie génique traditionnelle. Malheureusement, bien que nombreux agents correcteurs soient disponibles aujourd’hui, tels que des oligodéoxynucléotides simple-brins, des grands fragments d’ADN simple- et double-brins ainsi que des vecteurs rAAV, peu d’informations sont disponibles quant aux efficacités relatives de ces différentes approches sur un même système modèle. Nos travaux ont consisté tout d’abord à évaluer les efficacités de correction génique de ces approches. Puis, nous avons montré que le prétraitement des cellules par des agents causant des dommages à l’ADN permet d’augmenter l’efficacité de correction génique de ces approches. / Current strategies for gene therapy of inherited diseases consist in adding functional copies of the gene that is defective. Yet, an attractive alternative would be to correct the mutated gene that already exists in the affected individual. While many gene correction agents were described for their ability to correct mutations, no direct comparison of the repair efficiency has ever been made. Here, we present a side by side quantitative comparison of the correction efficiency of different forms of donor nucleic acids, including synthetic DNA oligodeoxynucleotides, large DNA fragments and sequences carried by a recombinant adeno-associated virus. Also, we show that a pretreatment of cells with doxorubicin (a topoisomerase II inhibitor) or with phleomycin (a glycopeptide antibiotic), both substances known to induce DNA damages, can increase the correction efficiency of the different repair tools.

No description available.

Oligodeoxynucleotides containing CpG motifs (CpG-ODN) have been shown to stimulate the innate immune system against a variety of bacterial, viral, and protozoan infections in a variety of vertebrate species. The objectives of this study were to investigate the immunostimulatory effect of CpG-ODN against Salmonella Typhimurium infection and the formulation and delivery of CpG-ODN by the in ovo route. Day-old broiler chicks or embryonated eggs (day 18th of incubation) received either 50 g of CpG-ODN, 50 g of non-CpG-ODN, or saline. At day four-post hatch, all birds were subcutaneously inoculated by Salmonella Typhimurium. Clinical signs, pathology, bacterial isolations from the air sacs, and mortality were observed for ten days following challenge. The survival rate of the birds that received CpG-ODN via in ovo or in vivo treatments was significantly higher than the control group. Salmonella Typhimurium level in the peripheral blood and pathology were significantly lower (p < 0.001) in CpG-ODN group compared to the control group. In order to investigate the effect of formulation of CpG-ODN, embryonated eggs (day 18th of incubation) were inoculated with either 50 g of CpG-ODN alone or CpG-ODN formulated with polyphosphazene, liposome, or Emulsigen®. Four days after administration of CpG-ODN formulations, the birds were challenged with E. coli by subcutaneous injection. Clinical signs, pathology, bacterial isolations from the air sacs, and mortality were observed for seven days following challenge. The birds that received either CpG-ODN or CpG-ODN formulated with polyphosphazene had significantly higher survival rates (30 and 60%) compared to the birds in groups receiving either non-CpG-ODN or saline. Bacterial loads in the air sacs were lower in groups treated with formulated CpG-ODN compared to the CpG-ODN alone or control groups. However, formulation of CpG-ODN with liposomes or Emulsigen® did not increase the immunoprotective effect against E. coli infection. We showed that treatment with CpG-ODN protects neonatal chickens against an intracellular bacterial infection and that co-treatment of CpG-ODN with polyphosphazene enhances the immunoprotective effect of CpG-ODN.

Oligodeoxynucleotides containing CpG motifs (CpG-ODN) have been shown to stimulate the innate immune system against a variety of bacterial, viral, and protozoan infections in a variety of vertebrate species. The objectives of this study were to investigate the immunostimulatory effect of CpG-ODN against Salmonella Typhimurium infection and the formulation and delivery of CpG-ODN by the in ovo route. Day-old broiler chicks or embryonated eggs (day 18th of incubation) received either 50 g of CpG-ODN, 50 g of non-CpG-ODN, or saline. At day four-post hatch, all birds were subcutaneously inoculated by Salmonella Typhimurium. Clinical signs, pathology, bacterial isolations from the air sacs, and mortality were observed for ten days following challenge. The survival rate of the birds that received CpG-ODN via in ovo or in vivo treatments was significantly higher than the control group. Salmonella Typhimurium level in the peripheral blood and pathology were significantly lower (p < 0.001) in CpG-ODN group compared to the control group. In order to investigate the effect of formulation of CpG-ODN, embryonated eggs (day 18th of incubation) were inoculated with either 50 g of CpG-ODN alone or CpG-ODN formulated with polyphosphazene, liposome, or Emulsigen®. Four days after administration of CpG-ODN formulations, the birds were challenged with E. coli by subcutaneous injection. Clinical signs, pathology, bacterial isolations from the air sacs, and mortality were observed for seven days following challenge. The birds that received either CpG-ODN or CpG-ODN formulated with polyphosphazene had significantly higher survival rates (30 and 60%) compared to the birds in groups receiving either non-CpG-ODN or saline. Bacterial loads in the air sacs were lower in groups treated with formulated CpG-ODN compared to the CpG-ODN alone or control groups. However, formulation of CpG-ODN with liposomes or Emulsigen® did not increase the immunoprotective effect against E. coli infection. We showed that treatment with CpG-ODN protects neonatal chickens against an intracellular bacterial infection and that co-treatment of CpG-ODN with polyphosphazene enhances the immunoprotective effect of CpG-ODN.

As respiratory syncytial virus (RSV) is a respiratory pathogen that causes significant morbidity and mortality in infants, there has always been great interest in the development of a vaccine. In the 1960s, children were immunized with formalin-inactivated (FI)-RSV vaccines. Not only did these vaccines fail to prevent infection, but in most cases they resulted in enhanced disease upon subsequent exposure to the virus. In the intervening years, studies in mice have led to the hypothesis that the enhanced disease is due to an aberrant Th2-biased immune response. Thus, we hypothesized that formulating FI-RSV vaccines with a Th1 promoting adjuvant, such as CpG oligoeoxynucleotides (ODN), would result in the induction of protective immunity against RSV without risk of deleterious effects. We observed in calves that parenterally delivered FI-bovine RSV (BRSV) formulated with CpG ODN resulted in a shift towards a Th1-biased or more balanced immune response that was protective against BRSV.<p> As RSV infects the lung mucosa, vaccines that induce mucosal immunity are desirable. Parenterally delivered vaccines typically induce systemic immunity with low mucosal immune response levels, whereas mucosally delivered vaccines induce systemic and mucosal immunity. However, upon mucosal delivery there is an increased chance of vaccine components being degraded or washed away prior to the induction of immunity. Thus, we added polyphosphazenes (PP) to our mucosal vaccine formulations. PP are synthetic polymers that form non-covalent complexes with other vaccine components, increasing their stability. Intranasally delivered FI-BRSV co-formulated with CpG ODN and PP performed better than FI-BRSV alone, or FI-BRSV formulated with either adjuvant individually, in terms of inducing protective immunity against BRSV in mice. Furthermore, mice that received intranasally-delivered FI-BRSV or BRSV F protein co-formulated with CpG ODN and PP developed higher levels of immunity and protection than mice that received parenterally delivered vaccines. Because of the similarities between BRSV and HRSV, co-formulation of intranasally delivered HRSV vaccines with CpG ODN and PP could prove important in the development of a safe vaccine against HRSV in humans.

As respiratory syncytial virus (RSV) is a respiratory pathogen that causes significant morbidity and mortality in infants, there has always been great interest in the development of a vaccine. In the 1960s, children were immunized with formalin-inactivated (FI)-RSV vaccines. Not only did these vaccines fail to prevent infection, but in most cases they resulted in enhanced disease upon subsequent exposure to the virus. In the intervening years, studies in mice have led to the hypothesis that the enhanced disease is due to an aberrant Th2-biased immune response. Thus, we hypothesized that formulating FI-RSV vaccines with a Th1 promoting adjuvant, such as CpG oligoeoxynucleotides (ODN), would result in the induction of protective immunity against RSV without risk of deleterious effects. We observed in calves that parenterally delivered FI-bovine RSV (BRSV) formulated with CpG ODN resulted in a shift towards a Th1-biased or more balanced immune response that was protective against BRSV.<p> As RSV infects the lung mucosa, vaccines that induce mucosal immunity are desirable. Parenterally delivered vaccines typically induce systemic immunity with low mucosal immune response levels, whereas mucosally delivered vaccines induce systemic and mucosal immunity. However, upon mucosal delivery there is an increased chance of vaccine components being degraded or washed away prior to the induction of immunity. Thus, we added polyphosphazenes (PP) to our mucosal vaccine formulations. PP are synthetic polymers that form non-covalent complexes with other vaccine components, increasing their stability. Intranasally delivered FI-BRSV co-formulated with CpG ODN and PP performed better than FI-BRSV alone, or FI-BRSV formulated with either adjuvant individually, in terms of inducing protective immunity against BRSV in mice. Furthermore, mice that received intranasally-delivered FI-BRSV or BRSV F protein co-formulated with CpG ODN and PP developed higher levels of immunity and protection than mice that received parenterally delivered vaccines. Because of the similarities between BRSV and HRSV, co-formulation of intranasally delivered HRSV vaccines with CpG ODN and PP could prove important in the development of a safe vaccine against HRSV in humans.

Bacterial DNA is immunostimulatory, and the motifs responsible for this activity are unmethylated CpG dinucleotides. Following cellular uptake, CpG-containing oligodeoxynucleotides (CpG ODN) are trafficked to the endosome where they bind Toll-like receptor 9 (TLR9) to initiate a signaling cascade that culminates in the release of numerous pro-inflammatory cytokines. Because of their immunostimulatory properties, CpG ODN are being clinically evaluated as treatments and vaccine adjuvants for infectious diseases, cancer, and allergic disorders. α2-Macroglobulin (α2M) is a human plasma protein that binds and modulates the activity of a variety of cytokines, growth factors, enzymes, and antigens. Upon proteolytic activation, α2M is converted to its receptor recognized form, α2M*, and rapidly binds to and is internalized by immune competent cells expressing the α2M* endocytic receptor, LRP, and is then trafficked to the endosome. Based on these interactions, α2M seems to play an important role at sites of infection and inflammation by controlling the level of proteinase activity, modulating cytokine signals, and enhancing antigen processing for the adaptive immune response. Here, we report the first evidence that α2M* binds and forms stable complexes with nucleic acids. We have characterized the mechanisms and stoichiometry of this interaction, examined the pH and temperature stability of these complexes, and identified structural variables in the nucleic acids, namely length, base composition, and chemical modifications, that affect the nature of this interaction. We hypothesized that CpG ODN incorporation into α2M* may alter their immunostimulatory properties. Murine macrophages (MΦs) treated with α2M*-ODN complexes respond more rapidly and produce a greater cytokine response than those treated with free CpG ODN alone. Treating human PBMCs with α2M*-ODN complexes likewise demonstrated their enhanced ability to elicit immune responses. This was due to more rapid uptake and CpG ODN protection from degradation by extracellular nucleases. Co-incorporation of both protein ligands and CpG ODN into α2M* yields ternary complexes; these may permit the simultaneous delivery of both protein antigens and adjuvants to immune competent cells, potentially greatly enhancing the adaptive immune response and protective immunity. Based on the findings that incorporation into α2M* confers enhanced immunostimulatory activity of CpG ODN, this technology may be exploited to improve CpG ODN-based therapeutics by increasing efficacy, minimizing side effects, reducing dosing requirements, and reducing cost. / Dissertation

Synthetic CpG containing oligodeoxynucleotides (ODNs) are recognized by Toll like Receptor 9 (TLR9) and induce a strong pro-inflamatory immune response. To date, four different CpG ODN classes have been described. K-Class ODNs (also known as B-ODN) are potent B cell activators and stimulate TNF

Male rat copulation is mediated by estrogen-sensitive neurons in the medial preoptic area (MPO) and medial amygdala (MEA); however, the mechanisms through which estradiol (E2) acts are not fully understood. We hypothesized that E2 acts through estrogen receptor α (ERα) in the MPO and MEA to promote male mating behavior. Antisense oligodeoxyneucleotides (AS-ODN) complementary to ERα mRNA were bilaterally infused via minipumps into either brain area to block the synthesis of ERα, which we predicted would reduce mating. Western blot analysis and immunocytochemistry revealed a knockdown of ERα in each brain region; however, compared to saline controls, males receiving AS-ODN to the MPO showed significant reductions in all components of mating, whereas males receiving AS-ODN to the MEA continued to mate normally. These results suggest that E2 acts differently in these brain regions to express sexual behavior and that ERα in the MPO, but not in the MEA, promotes mating.

The use of DNA-based therapeutics requires efficient delivery systems to transport the DNA to their place of action within the cell. To accomplish this, we investigated multiwalled carbon nanotubes (pristine MWCNT, p-MWCNT) functionalized with hydroxyl groups via 1,3-dipolar cycloaddition. In this way, we have obtained MWCNT-f-OH with improved stability in aqueous dispersions which is an advantageous property for their use in cellular environments. Afterwards, a carrier strand oligodeoxynucleotide (CS-ODN) was adsorbed to MWCNT-f-OH followed by hybridization with a therapeutic antisense oligodeoxynucleotide (AS-ODN). The amount of adsorbed CS-ODN, as well as the complementary AS-ODN and a non-complementary oligodeoxynucleotide (NS-ODN) as reference, was directly measured by radionuclide labeling of ODNs. We show that subsequent release of AS-ODNs and NS-ODNs was possible for MWCNT-f-OH above the melting temperature of AS-ODNs at 80 °C and under physiological conditions at different pH values at 37 °C. We also show a very low influence of p-MWCNT and MWCNT-f-OH on the cell viability of the bladder carcinoma (BCa) cell line EJ28 and that both MWCNT types were internalized by EJ28. Therefore, MWCNT-f-OH represents a promising carrier able to transport and release AS-ODNs inside cells.